Skip to main content

myCare-101 Clinical Trial

Personalized Therapy Biosimulation

Know how each cancer patient will respond to therapy before treatment

Sign up to Enroll

Personalized Cancer Therapy
Biosimulation Predicts

The most efficacious chemotherapy

The most effective targeted therapy

The most beneficial immunotherapy

Synergistic therapy combinations

Radiotherapy sensitivity or resistance

Every patient's tumor has a unique mutation profile

Standard care guidelines only
consider one mutation at a
time, resulting in low response
rates across cancer types

Treatment guidelines do
not consider mutational
interactions that often cause
drug resistance

Genome sequencing technology
has improved significantly but
today's analysis of the output
is inadequate

Current treatment guidelines typically
target one mutation with one drug, resulting in
low response rates across cancer types

AML
IDH2
Mutation
Standard Care Therapy
Enasidenib
NSCLC
MET Exon 14
Skipping Mutation
Standard Care Therapy
Capmatinib
GA
PD-L1
Mutation
Standard Care Therapy
Pembrolizumab

Predict responders and
non-responders prior to treatment

Identify optimal therapies for non-responders

Why biosimulate cancer
therapy responses?

whyboisimulate

Know response before treatment

Select personalized therapies

Avoid ineffective treatments

Improve patient outcomes

How does personalized therapy biosimulation work?

Personalised Biosimulation workflow

Biosimulate a patient’s multi-omic profile to predict and rank individual patient responses to millions  
of drug combinations by identifying oncotecture master regulators, mechanisms of resistance and  
conducting signaling pathway impact analysis.

Therapy biosimulation reports predict each
patient's unique response to cancer treatments

Singula Report

SINGULA™

Predicts personalized response to Standard Care therapies for front-line patients

Download Sample Report

VENTURA™

Predicts and ranks personalized response to combinations of
FDA-approved drugs including off-label and non-oncology drugs for refractory patients

Download Sample Report
Ventura Report

Cellworks biosimulation predictions proven
accurate across indications

aml mds

AML and MDS

90% Cellworks Therapy Response Prediction Accuracy

gbm

GBM

Cellworks Predicted SUPERIOR OS of patients treated with temozolomide

pdac

PDAC

94% Cellworks Therapy Response Prediction Accuracy

myCare-101 Clinical Trial Process

myCare101 Trial Process

Who can participate in myCare-101?

Physicians treating patients utilizing NGS reports for any of the listed
  cancer indications can participate

  • Bladder
  • Bone
  • Brain
  • Breast
  • Esophagus and Stomach
  • Extragonadal Germinal Cell Tumors
  • Genital Tract, Lower - Female
  • Genital Tract, Lower - Male
  • Head and Neck
  • Kidney
  • Large Intestine and Anus
  • Leukemia
  • Liver and Bile Duct
  • Lung and Bronchus
  • Lymphoma - Hodgkin
  • Lymphoma - Non-Hodgkin
  • Melanoma
  • Mesothelioma
  • Myelodysplastic Syndrome
  • Myeloma
  • Myeloproliferative Disease
  • Ovary and Fallopian Tube
  • Pancreas
  • Prostate
  • Skin
  • Small Intestine
  • Soft Tissue
  • Testes
  • Thymus
  • Urothelial Carcinoma
  • Uterus
  • Cancer of Unknown Primary
  • Bladder
  • Bone
  • Brain
  • Breast
  • Esophagus and Stomach
  • Extragonadal Germinal Cell Tumors
  • Genital Tract, Lower - Female
  • Genital Tract, Lower - Male
  • Head and Neck
  • Kidney
  • Large Intestine and Anus
  • Leukemia
  • Liver and Bile Duct
  • Lung and Bronchus
  • Lymphoma - Hodgkin
  • Lymphoma - Non-Hodgkin
  • Melanoma
  • Mesothelioma
  • Myelodysplastic Syndrome
  • Myeloma
  • Myeloproliferative Disease
  • Ovary and Fallopian Tube
  • Pancreas
  • Prostate
  • Skin
  • Small Intestine
  • Soft Tissue
  • Testes
  • Thymus
  • Urothelial Carcinoma
  • Uterus
  • Cancer of Unknown Primary
Download Full List of over 150 indications

Supported NGS Report Vendors

Sema4

Foundation Medicine

Caris

Tempus

MSK-IMPACT

Illumina

ngs-report

Learn more about the Cellworks
myCare-101 Clinical Trial

RESOURCES

Information, publications and white papers at your fingertips

SIGN UP TO ENROLL

Top